Navigation Links
Targeting the Adrenal Gland Could Be Key Against Heart Failure

Scientists have staved off heart failure in animals by using gene therapy to shut down the adrenal gland’s excessive// output of fight or flight hormones such as epinephrine and norepinephrine. By blocking GRK2, an important regulatory enzyme, they cut the hormone production that forces the heart to pump too hard, leading to heart failure. Such a novel approach – targeting the adrenal gland in addition to the heart – provides a potential new strategy against heart failure, and could lead to a new class of drugs.

The researchers, led by Walter Koch, Ph.D., W.W. Smith Professor of Medicine and director of the Center for Translational Medicine in the Department of Medicine at Jefferson Medical College, report their findings in the journal Nature Medicine.

“The emphasis has always been in treating right at the heart,” says Stephen B. Liggett, M.D., director of the cardiopulmonary genomics program at the University of Maryland School of Medicine, who has written an accompanying editorial.

“Despite our best efforts, about half of all heart failure patients die within five years of diagnosis, so clearly something new is needed. These results add a completely new dimension to the way physicians might be able to intervene to improve heart failure therapy.”

When an individual’s heart begins to fail, the sympathetic nervous system, attempting to compensate for the weakened heart, goes into overdrive, pumping out increasing levels of stimulants – catecholamines such as epinephrine and norepinephrine, making a bad situation worse. The typical treatment – beta blockers – inhibit the beta adrenergic receptors on the heart, blocking the hormones that force the heart to work overtime.

Dr. Koch’s group focused instead on the source of catecholamines – the adrenal gland. It discovered that in heart failure, the extra hormones “desensitize” the adrenal’s alpha 2 adrenergic receptors because of a rise in GRK2, or G protein-cou pled receptor kinase 2, essentially turning them off. Using gene therapy to block adrenal gland GRK2 in animals in heart failure, the scientists were able to get the alpha 2 receptors working again and also found that the beta adrenergic receptors on the heart worked better as well.

“We’ve shown that in the adrenal gland, resetting the alpha adrenergic receptors by inhibiting GRK2 causes more normal regulation and the proper feedback control, and catecholamines are lowered,” explains Dr. Koch, who also heads the George Zallie and Family Laboratory of Cardiovascular Gene Therapy in the Department of Medicine. “If less catecholamine is presented to the heart, then the beta receptors restabilize and that improves heart function. The heart is allowed to relax and get better.”

“This is the first time anyone has identified a molecular mechanism involved in such sympathetic overdrive in heart failure,” adds study first author Anastasios Lymperopoulos, Ph.D., a postdoctoral fellow in the Center for Translational Medicine, and means that adrenal gland GRK2 becomes a new target for heart failure medications.

“GRK2 inhibitors would be a totally new class of drugs if they come on the market,” Dr. Koch says, adding that eventually, human gene therapy for heart failure could be feasible.
Source-Newswise
SRM
'"/>




Related medicine news :

1. Novel Technique For Targeting Small-Cell Lung Cancer
2. Targeting PARP1 Is Effective In Protecting HD Cells from Damage
3. Ad Campaign Targeting Republicans On Medicare Prescription Drug Program
4. By Targeting Specific Germs, Hospital Hopes to Improve Pneumonia Treatment
5. Highly Potent TB Strain Plays Favorites Targeting Specific Ethnic Groups
6. New Asthma Medicine Targeting Vulnerable Inner-City Children Tested
7. Targeting a Single Gene Could Inhibit Bone Decay and Stimulate Bone Growth
8. Researchers Find Stem-cell Therapy Effective in Targeting Metastatic Cancer
9. Targeting SOCS-3 can Control Obesity
10. Sex Abstinence Programs Targeting School-goers may Not Produce Desired Effect , Study
11. Adrenal Suppression not predicted by inhaled corticosteroids
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/11/2016)... ... February 11, 2016 , ... Husted Kicking has ... Diego, CA, on February 6th & 7th, 2016 according to kicking coach Michael Husted. ... not invited to the NFL’s combine in Indianapolis,” says Husted. “The NFL uses a ...
(Date:2/11/2016)... AZ (PRWEB) , ... February 11, 2016 , ... As ... with support of the Million Dollar Round Table Foundation (MDRTF), has gifted $10,000 to ... according to Colleen’s Dream Foundation President Billy Cundiff. , “We are honored to support ...
(Date:2/10/2016)... ... February 10, 2016 , ... Early this week, Team Iconic at J. ... Nestlé KITKAT as the first global confectionery brand sourced from 100% sustainable cocoa. , ... quality of their product, through activities that focus on better farming, better lives and ...
(Date:2/10/2016)... Fort Walton Beach, Florida (PRWEB) , ... February ... ... that the innovative weather-forecasting company is unveiling its revolutionary new 2.0 version at ... new platform, MetLoop has “put the power of the world's most advanced weather ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... Guard, to associations of medical professionals throughout the country. The Guard was specifically ... assessments, policies and procedures, employee training, regulatory updates, and compliance coaching. , In ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... England och PITTSBURGH ... Erbjudandet lämnas inte, och detta pressmeddelande ... indirekt, i eller till, och inga anmälningssedlar ... av aktieägare i, något land där Erbjudandet, ... accept av Erbjudandet skulle strida mot tillämpliga ...
(Date:2/10/2016)... A new report from business intelligence provider GBI Research ... Alzheimer,s disease market will more than double from just under $5 billion in ... Rate (CAGR) of 11%. Canada , France ... Spain , the UK, and Japan , and ... --> Canada , France , ...
(Date:2/10/2016)... , Feb. 10, 2016 Urologix, the market ... treatment of Benign Prostatic Hyperplasia (BPH), announces new private ... Keswani , a medical device industry veteran of more ... Limited Liability Company.  Plymouth, Minn. ... lines, Cooled ThermoTherapy™ and Prostiva® RF Therapy, will continue ...
Breaking Medicine Technology: